Three Rivers Pharmaceuticals^® welcomes you to learn more about the company and its products. Established in 2000, Three Rivers Pharmaceuticals devotes its efforts and resources to developing, manufacturing, and marketing pharmaceutical therapies which are indicated for diseases/medical conditions requiring specialized treatment. Currently, Three Rivers Pharmaceuticals markets prescription drugs in both the U.S. and internationally, in the therapeutic categories of antiviral and antifungal agents.

The company has continued to grow its portfolio into the branded market with the acquisition of AMPHOTEC^®/AMPHOCIL^®. This product is currently approved and actively marketed in over 40 countries worldwide.

Three Rivers Pharmaceuticals has a strong presence in the Hepatitis C market with the launch of Ribasphere^® Tablets and Ribasphere^® RibaPak^® (ribavirin, USP). The company expanded its Hepatitis C franchise with the acquisition of INFERGEN^® from Valeant Corp. With the development and acquisition of these specialized therapies, Three Rivers Pharmaceuticals has helped many patients around the world improve the quality of their treatment.